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INTRODUCTION
A Study of Soft Tissue Sarcoma
Introduction
Soft tissue sarcomas comprise a group of relatively rare, anatomically and 
histologically diverse neoplasms that share a common embryologic origin arising 
primarily from tissues derived from the mesoderm with the notable exception of 
neurosarcomas, primitive neuro ectodermal tumors (PNET) and possible Ewing’s 
sarcoma, which are thought to arise from tissues of ectodermal origin. 
AIM OF THE STUDY
Aim of the Study
1. To find out the incidence of soft tissue sarcoma in Coimbatore Medical College 
Hospital.
 
2. To evaluate the etiopathogenesis of soft tissue sarcomas.
 
3. To evaluate the diagnostic modalities availed.
4. To evaluate the outcome of surgery for soft tissue sarcomas. 
5. To evaluate the role of radiotherapy and chemotherapy in soft tissue sarcomas.
 
6. To evaluate the results following combined modality treatment of soft tissue 
sarcomas. 
7. To evaluate the incidence of recurrence and the causes for the recurrence.
REVIEW OF LITERATURE
Review of Literature
Incidence 
Soft tissue sarcoma accounts for < 1% of adult malignancies and 15% of pediatric 
malignancies. 
Etiology 
No specific etiologic agent is identified in the overwhelming majority of patient 
with soft tissue sarcoma. Risk factors of STS include the following:
1. Previous radiation exposure 
The risk of post radiotherapy sarcomas increases with increasing dosage. By 
definition, radiotherapy induced sarcomas arise no sooner than 3 yrs after therapeutic 
radiation and often arise decades later. Sarcomas occurring after radiation exposure are 
most commonly malignant fibrous histiocytoma.
2. Environmental Factors 
Chemical exposure to phenoxy acetic acid, found in herbicides, chlorophenol, 
found in wood preservatives are associated with STS. Thorotrast, vinyl chloride, arsenic 
are associated with hepatic angio sarcoma. 
3. Chronic Lymphedema
Chronic Lymphedema such as that experience after axillary dissection has been 
associated with Lymphangio sarcoma (stewart – Treves syndrome)
4. Chronic Inflammatory process may a risk factor 
Agents such as shrapnel, bullets, intra muscular iron injections and foreign body 
implants have been implicated.
5. Genetic predisposition 
Specific inherited genetic alterations have been associated with an increased risk 
of STS. Patients with Gardner’s syndrome (Familial polyposis) have a higher than 
normal incidence of desmoids.
Patients with germline mutations in the tumor suppressor gene p53 (Li- Fraumeni 
syndrome) have high incidence of sarcomas. 
Patients with von Recklinghausen’s disease who have abnormalities in the 
Neurofibromatosis type I tend to develop neurofibrosarcoma.
Soft tissue sarcoma can occur in patients with hereditary retinoblastoma as a 
second primary malignancy.
6. Chromosome rearrangements
A number soft tissue tumors both benign and malignant have been found to have 
consistent chromosomal abnormalities which in many cases may be diagnostic. 
     
Chromosomal translocations are the most common cytogenetic abnormality in 
soft tissue tumors. 
Classification
HISTOLOGIC CLASSIFICATION OF STS
FIBROUS TUMORS   
Fibro sarcoma 
a. Adult fibro sarcoma
b. Congenital or infantile fibro sarcoma 
c. Inflammatory fibro sarcoma (inflammatory myofibroblastic tumor)
FIBROHISTIOCYTIC TUMORS
1. Intermediate tumors 
Dermatofibrosarcoma protuberans 
2. Malignant fibrous histiocytoma.
a. Storiform- pleomorphic fibrous histiocytoma 
b. Myxoid fibrous histiocytoma 
c. Giant cell fibrous histiocytoma (malignant giant cell tumor of soft parts)
d. Xanthomatous (inflammatory type) fibrous histiocytoma.
LIPOMATOUS TUMORS 
Liposarcoma 
a. Well- differentiated liposarcoma 
i.) Lipoma-like liposarcoma 
ii.) Sclerosing liposarcoma
iii.) Inflammatory liposarcoma
b. Myxoid liposarcoma
c. Round cell (poorly differentiated myxoid) liposarcoma
d. Pleomorphic liposarcoma
e. De- differentiated liposarcoma
SMOOTH MUSCLE TUMORS 
1. Rhabdomyosarcoma  
a. Embryonal rhabdomyosarcoma
b. Botryoid rhabdomyosarcoma
c. Spindle cell rhabdomyosarcoma
d. Alveolar rhabdomyosarcoma
e. Pleomorphic rhabdomyosarcoma
2. Rhabdomyosarcoma with ganglionic differentiation (ectomesenchymoma)
TUMORS OF BLOOD AND LYMPH VESSEL
1. Angiosarcoma and Lymphangiosarcoma
2. Kaposi’s sarcoma 
3. Follicular dendritic cell sarcoma 
PERIVASCULAR TUMORS 
1. Malignant glomus tumor 
2. Malignant hemangiopericytoma 
SYNOVAL TUMORS 
1. Synovial sarcoma
 
a. Biphasic (Fibrous and Epithelial) synovial sarcoma 
b. Monophasic (Fibrous or Epithelial) synovial sarcoma 
2. Malignant giant cell tumor of tendon sheath 
MESOTHELIAL TUMORS
 
1. Malignant solitary fibrous tumor pleura and peritoneum 
2. Diffuse mesothelioma 
a. Epithelial
b. Fibrous 
c. Diffuse
NEURAL TOMORS 
1. MPNST (malignant schwannoma, neurofibrosarcoma)
a. Malignant Triton tumor (MPNST with Rhabdomyosarcoma)
b. Glandular MPNST (malignant glandular schwannoma)
c. Epithelioid MPNST (malignant epithelioid schwannoma)
2. Malignant granular cell tumor 
3. Clear cell sarcoma (malignant melanoma of a soft parts)
4. Malignant melanocytic schwannoma 
5. Gastrointestinal autonomous nerve tumor (plexosarcoma)
6. Primitive neuroectodermal tumor 
a. Neuroblastoma 
b. Ganglioneuroblastoma
c. Neuroepithelioma (peripheral neuroectodermal tumor)
d. Extraskeletal Ewing’s sarcoma 
PARAGANGLIONIC TUMORS
1. Malignant paraganglioma 
EXTRASKELETAL CARTILAGINOUS AND OSSEOUS TUMORS
1. Extraskeletal chondrosarcoma 
a. Well- differentiated 
b. Myxiod 
c. Mesenchymal
PLURIPOTENTIAL MESENCHYMAL TUMORS 
1. Malignant mesenchymoma 
MISCELLANEOUS TUMORS
1. Alveolar soft part sarcoma 
2. Epithelioid sarcoma 
3. Malignant extrarenal rhabdoid tumor
4. Desmoplastic small cell tumor 
PATHOLOGY
The term sarcoma is Greek for “Fish flesh”, referring tumor’s tendency to feel 
fleshy when palpated. Mesodermal cells give rise to the connective tissues distributed 
throughout the body including pericardium, pleura, blood vessel, endothelium, smooth 
and striated muscle, bone, cartilage and synovium are the cells from which all sarcomas 
originate. Consequently, sarcomas develop in a wide variety of anatomic sites.
Approximately one half of all STS occurs in the extremities (lower- 38%, upper- 
15%), where, the most common histopathologies are liposarcoma 30% and malignant 
fibrous histiocytoma 22%. 
Retroperitoneal intra abdominal tumors comprise 14% of all STS with 
liposarcoma, the predominant histropathologic sub type (41%). 
Visceral STS account for 13% and head and neck for 5%. Several histologic types 
of sarcoma have been characterized. This characterization can be difficult and is aided 
by electron microscopy. 
Immuno histochemical staining for proteins such as vimentin, S-100, desmin, 
factor VIII, Keratin, Myoglobin and Actin often facilitates reliable histo typing.
One of the pathologic hallmark of STS distinguishing it from carcinoma is the 
tendency of STS to spread by hematogenous means. 
Metastases are uncommon in patients with low grade STS in contrast to patients.
Lymphnode metastasis from STS is rare occurring in less then 3% of adult patients. The 
histologic sub types with highest incidence of lymph node metastasis are:
• Epithelioid sarcoma 16.7% 
• Embryonal Rhabdomyosarcoma 13.6%
• Angiosarcoma 13.5% 
• Malignant fibrous histiocytoma 5%
• Synovial sarcoma 
Clinical Presentation
• Most patients present with painless mass, although the pain is noted in 1/3rd of 
the patients.
• Non-specific abdominal discomfort and GI symptoms in intra abdominal or 
retroperitoneal STS.
• Delay in diagnosis is common with the most common differential diagnosis 
for extremity and trunk lesions being hematoma or “pulled muscle”.
Diagnosis
          Physical examination     
• Assessment of the size and mobility of the mass, relationship to fascia 
(superficial Vs deep) and near by neuro vascular and bony structures.
• A site- specific neuro vascular examination and assessment of regional 
lymph nodes.
Investigations 
                         1. Biospsy – The primary thrust of biopsy is to obtain adequate tissue for 
definitive histopathologic confirmation, to evaluate grade, and to identify prognostic 
factors that would alter the approach to definitive treatment.
• Indications 
i. Any soft tissue mass in an adult that is symptomatic or enlarging 
is greater then 5cm in size.
ii. Any new soft tissue mass that persists beyond 4-6 weeks 
• Technique
Small superficial mass (<5cm  )- excisional biopsy with clear margins 
in the preferred approach.
     Large  mass-  incisional  biopsy  with  a  longitudeinal  incision 
(extremity  lesions)  to  facilitate  subsequent  wide  local  excision. 
Incision  should  be  centered  over  the  mass  at  its  most  superficial 
location. Care should be taken to raise flaps. Meticulous hemostasis 
should  be  ensured  to  prevent  dissemination  of  tumor  cells  into 
adjacent tissue planes.
                             At definitive resection of a previously biopsied sarcoma the previous 
scar should be excised enbloc with the tumor. Biopsy specimens should be sent fresh, 
sterile and anatomically oriented for pathologic analysis.
       
Fine needle aspiration cytology 
                         FNAC has been examined by a number of authors but is usually 
confined to the confirmation of recurrence, rather than for the primary diagnosis.
2. CT Scan 
        Provides information on the size of the lesion and its relationship to 
adjacent structures and organs
3. MRI
• Examination of choice for imaging of soft tissue masses 
• Enhances the contrasts between tumor and muscle, and tumor and 
adjacent blood vessel. 
• Provides superior 3 dimensional definition of fascial planes 
(These substantial advantages allow for improvement assessment 
of resectability with pre operative MRI evaluation).
4. Newer investigatory techniques 
Phosphorus magnetic resonance spectroscopy (31P-MRS)
• It is a form of noninvasive resonance spectroscopy that detects 
phosphorus containing metabolites
• Employed to evaluate sarcoma inorganic – to – organic phosphate 
ratios. 
• In – vivo metabolic assessment of response to anti- neoplastic 
therapy 
5. Positron emission tomography (PET scan)
• By evaluating tumor metabolic activity PET scan may permit 
noninvasive assessment of tumor grade.
6. Radionuclide Scintigraphy 
• Thalium – 201 and Gallium – 67 in osseous sarcoma 
• Gallium – 67 in STS and in the assessment of patients with 
metastatic and recurrent STS.
7. Radiolmmunoscanning                       
                         125I radiolabelled anti – sarcoma localizes foci of metastatic disease.
Staging 
The American joint committee for cancer staging (AJCC) system for staging 
STS believes on histologic grade, tumor size, nodal status and presence or absence of 
distant metastasis.
Histologic grading of sarcomas is found to be the critical determined of 
outcome. Histological grading is based on the following histopathologic criteria:
  i. Cellularity 
   ii. Cellular pleomorphism 
   iii. Mitotic activity 
   iv. Necrosis 
The AJCC staging system for STS 
 
Histologic grade of malignancy (G)
Sx Grade cannot be assessed 
S1 Well differentiated 
S2 Moderately differentiated 
S3 Poorly differentiated 
S4 Undifferentiated 
Primary Tumor (T)
Tx primary tumor cannot be assessed 
T0 No evidence for primary tumor
T1 Tumor 5cmor smaller in greatest dimension 
T2 Tumor larger than 5cm greatest dimension
Regional lymph node status (N)
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases
N1 Regional lymph node metastases
Distant metastases (M)
Mx presence of distant metastases cannot be assessed 
M0 No distance metastases 
M1 Distant metastases
Staging /Grouping/Grading
IA G1 T1 N0 M0
IB G1 T2 N0 M0
IIA G2 T1 N0 M0
IIB G2 T2 N0 M0
IIIA G3, G4 T2 N0 M0
IIIB G3, G4 T2 N0 M0
IVA Any G Any T N1 M0
IVB           Any G Any T Any N M1
Binary grading system for STS employed at memorial sloan – kettering cancer 
Center (MS-KCC) 
Low grade STS High grade STS 
Good Differentiation           Poor differentiation 
Hypo cellar Hyper cellular 
Increased stroma Minimal stroma
Hypo vascular Hyper vascular
Minimal necrosis Significant necrosis
<5 mitoses/ 10 HPF >5 mitoses / 10 HPF
MS-KCC sarcoma prognostic factors 
Favorable Factors Adverse Factors
Size <5cm >5cm
Site Superficial Deep
Histologic Low High    
  
Prognostic factors 
    A through knowledge of the clinico pathologic factors known to have an impact on 
outcomes is essential in formulating a treatment plan for patents with STS.
Summary of significant prognostic factors for extremity STS
Outcome variable                                        Factors found to be prognostic
         by multi- variate analysis
 
Local recurrence (only)        Presentation with recurrent
       disease inadequate surgical margin      
                                                (gross or microscopically positive)                         
Development of distant High histologic grade
Metastasis Deep location size > 5cm
Post metastasis survival Age at metastasis > 60 yrs time from   
presentation to metastasis to site(s) other 
then single lung
Disease related mortality High histologic grade deep location size >
5cm
TREATMENT 
Surgery – Primary therapy and results 
            For patients wit localized disease, surgical treatment is the corner stone of 
treatment.  The surgical approach to sarcomas is predicted on one pathologic fact and its 
clinical correlate.
 STS tend to expand and infiltrate tissue planes, producing a pseudo capsule 
composed of normal host tissue inter laced with fimbriae of tumor.
 For patients with alimb sparing option a multimodality approach employing limb-
sparing surgery combined with adjuvant chemo or radiotherapy yields local control and 
disease related survival rates comparable to amputation, while preserving a functional 
extremity.
Currently at least 85% of patients with localized extremity sarcomas can undergo 
limb sparing procedures.
Surgical Approach:
           A tissue diagnosis is made.  Pre-operative imaging studies (CT scan/MRI) have 
enabled accurate prediction resectability.
          Planned resection should emcompass the skin, subcutaneous tissue and soft tissues 
adjacent to the tumor, including the previous biopsy site and any associated drain sites 
or wound complications.
        There are no data to support compartmental or large muscle group resections over 
wide local excision with negative margins.
        Tumor should be excised with a 2-3 cm margin of normal surrounding tissue since 
there are good adjuvant approaches to facilitate local control this ideal target margin is 
frequently compromised as opposed to attempting major vascular or bony section.
         Adjuvant radiation therapy is indicated metal clips should be placed at the margins 
resection to facilitate radiation field planning.
         Drain sites should be positioned close to the wound to simplify treatment of a 
possible nature local recurrence.
         There is no role for routine regional lymph node dissection.  Therapeutic lymph 
node dissection (curative) results in a 34% actual survival patients with regional lymph 
node  involvement  who  has  no  evidence  of  extra  nodal  disease  should  therefore 
therapeutic lymphadenectomy.
Radiation Therapy – Neo-adjuvant and Adjuvant
           Radiation therapy alone has been employed as primary treatment for STS for 
patients with locally advanced disease or for patients who present with stage IV 
metastatic disease.
Efforts to use RT as primary treatment have demonstrated that 
1. High doses (>6500cGy) are required to achieve local control rates of 30% - 60%
2. Local control rate is inversely proportional to tumor size.
In general, local control rates with RT alone are inferior to those following surgery.  
Primary RT should therefore be reserved for patients.
i)   Who are medically unfit
ii)  Who have technically unresectable tumors
           iii) Who refuse surgery as initial treatment
Pre-operative RT has several theoretic advantages:
1. The unmanipulated tunor allows for a smaller treatment field than 
postoperative radiation.
2. Sterilization of tumor cells leads to reduced risk of intra vascular and would 
seeding with tumor cells at surgery.
3. Reduction in tumor volume increases resectability rates  (The adverse effects 
of preoperative radiation on wound healing balance these theoretic advantages)
              Adjuvant external beam RT is designated to treat residual microscopic disease 
that extends beyond the primary tumor mass and the margin of resection.
Adjuvant RT has also been delivered using the brachy therapy technique.
• Involves either permanent placement of radioactive sources (gold- 98 or iodine- 
131)
• Temporary placement of an interstitial implant with after loading catheters 
positioned in to the tumor bed at surgery (usually iridium- 192) on the 5th  or 7th 
postoperative days to deliver 42 to 60 Gy over the following 4 to 6 days 
Chemotherapy – Neoadjuvant and Adjuvant 
         Tumor response to preoperative chemotherapy provides significant prognostic 
information and identifies sub group of patients most likely to respond to adjuvant 
chemotherapy.
Agents used:
          Doxorubicin based neo adjuvant CT (CYVADIC regime-cyclophosphamide, 
adriamycin, dacarbazine with or without vincristine)
The combination  resulting in  the highest  response  rate  in  STS is  doxorubicin 
(60mg/m2).  For  younger  patients  who  can  tolerate  myelosuppression  the  dose  of 
doxorubicin can be increased 75mg/m2 with hematopoietic growth factor support. 
The dose of doxorubicin (60mg/m2) and infosfamide (7.5gm/m2) with or without 
DTIC 9900mg/m2). For younger patients who can tolerate myelosuppression the does of 
doxorubicin can be increased 75mg/m2 with hematopoietic growth factor support. 
 The does of doxorubicin and DTIC should be given by continuous infusion over 
4 days to decrease the risk of cardio toxicity and the severity of nausea and vomiting. 
Ifosfamide should be divided and given daily over 3 days and given with mesna for 
bladder protection.  
Physicians may choose single agent doxorubician or doxorubicin and DTIC for 
palliation  in  patients  who  may  not  tolerate  combined  doxorubicin  and  ifosfamide. 
Doxorubicin  (Adriamycin)  and  ifosfamide  are  the  most  active  single  agents  in  the 
treatment of STS, with response rates of 15% to 35% in various studies.  
A dose response relationship for doxorubicin has been observed in randomized 
trials dose rates 60 – 79 mgs/m2 every weeks are generally superior to does rates of 50 
mg/m2, ifosfamide, an analogue of cyclophosphamide, also demonstrates a steep dose 
response curve.
Ifosfamide  is  currently  the  most  active  salvage  agent  for  patients  in  whom 
doxorubicin-containing regimens have failed.
Treatment of locally recurrent and metastatic sarcoma
Local recurrence 
• Recurrent disease will develop in at lease 1/3rd of patients with a median 
disease free interval of 18months.
• Local recurrence rates varies with the primary site.
• Highest for retroperitoneal and head and neck sarcomas.
This is in part to the fact that adequate surgical margins are technically more 
difficult to attain these locations.
In addition, employment of high dose adjuvant RT is often limited in these sites of 
nodules arising in the surgical scar or radiation port.
After a staging evaluation, patients with isolated local recurrence should undergo 
re-operation.
If no prior RT was employed, adjuvant RT should be used after surgery.
Recent investigatory Treatment  :  
Regional perfusion of cytotoxic agents.
Cisplatin hyperthermic limb perfusion in extremity sarcoma patients.
High-dose recombinant TNF-a in combination with interferon-y and mephalan.
Metastatic disease
Most common site for metastasis is the lung (indeed, the lung is the only site of 
recurrence in approximately 50% of all patients.) Primary GI sarcomas metastasize to 
liver via the portal system.  All patients with suspected metastasis should be evaluated 
by chest CT – scanning.
Surgical treatment for metastatic disease
Appropriate patient selection for surgical approach for pulmonary metastasis is 
critical.
The criteria agreed upon are:
1. The primary tumor is controlled or is controllable.
2. There is no extra thoracic disease.
3. The patient is a medical candidate for thoracotomy.
4. Complete resection of all disease appears possible.
Prognostic Factors:
1. A shorter disease-free interval and incomplete pulmonary resection are adverse 
prognostic factors for survival for patients with pulmonary metastasis.
2. The presence of multiple metastatic pulmonary nodules (> 3) is an adverse 
prognostic factor.
3. Tumor doubling time (TDT)
The most important prognostic factor influencing survival is the ability to resect all 
disease completely.
Wedge excision with negative margins is the procedure of choice for patients with 
isolated pulmonary metastasis.
Lobectomy or pneumonectomy is considered in case of anatomic proximity of 
metastatic lesion to pulmonary artery, vein or major bronchus.
Multiple ipsilateral and bilateral lesions are not contraindications. Bilateral lesions 
can be approached by staged thoracotomies, median sternotomy, simultaneous, bilateral 
anterior thoracotomies. unilateral isolated lesions may be amenable to thoracoscopic 
resection.
Systemic therapy:
Patients with unresectable pulmonary metastasis or extra pulmonary metastasis 
are best treated with systemic chemotherapy.
Doxorubicin based regimens remain the standard therapy for advanced soft tissue 
sarcomas.
SPECIFIC ANATOMIC SITES
RETROPERITONEAL SARCOMAS
15% of all sarcomas
Most common histologic subtypes are:
• Liposarcoma 42% of cases
• Leiomyosarcoma 26% of cases 
Fibrosarcoma 6% of cases
Presenting symptoms and signs:
Abdominal mass-80%
Pain at presentation – 50%
Non-specific gastrointestinal symptoms 
Neurologic symptoms (primarily sensory) – 27%
Weight loss-7
Investigations:
CT scan and MRI
• Assessment of te consistency of the mass (cystic or solid components, associated 
necrosis)
• Pinpoint the precise anatomic location and exent of any regional disease. 
Confirms the function of contralateral kidney.
Differential Diagnosis
Testicular neoplasm
Physical examination of testis, B-HCG and AFP, testicular ultrasound helps in 
differentiating.
Biopsy
In general, pre-operative needle biopsy should not be performed for most 
retroperitoneal tumors.  For clearly unresectable lesions, or incases in which physical 
examination or laboratory studies suggest lymphoma or germ cell tumor, a needle 
biopsy may facilitate the diagnosis.
Open biopsy or complete resection at exploratory laparotomy is the preferred 
means of establishing the diagnosis.
Treatment of retroperitoneal STS
Surgical resection with margins is the standard primary treatment. [With the 
possibility of en bloc multi organ resection to achieve negative margins (kidney, colon, 
or pancreas), all patients should have pre-operative bowel preparation and assessment of 
bilateral renal function by CT scan]
Most common reasons for unresectability:
• Major vascular involvement (aorta, IVC), peritoneal implants, or distant 
metastasis.
Partial resections/Debulking have been performed, but there is no evidence that 
partial resection improves survival.
Gastrointestinal sarcomas
Gastrointestinal sarcomas are uncommon, accounting for 4% of all sarcomas.  The 
most common histologic subtype is leiomyosarcoma.  With the exception of the 
oesophagus, which accounts for 5% of all GI sarcomas, the frequency of GI sarcomas 
declines as one moves distally along the gastrointestinal tract, with stomach, small 
bowel, and colorectal sarcomas accounting for 50, 30 and 15% of GI sarcomas, 
respectively.
Presenting symptoms and signs of GI sarcomas are similar to those of carcinomas 
arising in the same segment of the gastrointestinal tract.
Diagnosis of GI sarcomas is often established pre operatively and is frequently 
made when the patient undergoes laparotomy for a mass in the small bowel or colon.
Treatment for GI sarcomas
The choice of appropriate surgical procedure for GI sarcomas is based on tumor size, 
anatomic site, and the fact that these sarcomas rarely spread to involve regional lymph 
nodes.
• For localized gastric lesions, wedge resection with negative margins is the 
procedure of choice.
• More extensive gastric lesions may require total gastrectomy or en bloc resection 
of adjacent organs.
• Duodenal sarcomas like other duodenal malignancies may require 
pancreaticoduodenostomy to achieve negative resection margins.
• Small bowel and colon lesions should be treated wit segmental resection.
• Extensive lymph node dissection or removal of grossly uninvolved mesentery is 
not required.
• Results from recent limited series have shown no benefit to adjuvant 
chemotherapy or radiotherapy for patients with gastrointestinal sarcomas.
Complete resection of isolated peritoneal or hepatic metastasis improves survival 
and should be attempted if feasible in good-risk patients.
Head and neck sarcomas 
Head and neck sarcomas are uncommon, accounting for only 4% of all sarcomas 
and less than 1% of head and neck malignancies in adults.
The most common histologic subtypes in adults are:
1. Fibrosarcoma 18%
2. Malignant fibrous histiocytoma 16%
3. Rhabdomyosarcoma 15%
Methods of diagnosis, imaging and biopsy for head and neck sarcomas do not 
differ substantially form those for other head and neck tumors.
Treatment for Head and Neck Sarcomas
Wide surgical excision with negative margins is the therapeutic mainstay for head 
and neck sarcomas.
Regional lymph node metastases are rare.  In the absence of clinically positive 
lymph nodes routine lumpadenectomy is not required.
Adjuvant radiotherapy should be considered whenever there is doubt as to the 
adequacy of surgical margins or the location of the tumor precludes complete excision.
As with sarcomas elsewhere, there is no clearly defined role for adjuvant 
chemotherapy.
MATERIALS AND METHODS
MATERIALS AND METHODS
This was a conducted for a period of 2 years. In this study, 40 patients from 
various units were analyzed. All the newly diagnosed patients and patients diagnosed 
outside and referred to Coimbatore Medical College Hospital for further evaluation and 
management were included in the study.
A detailed history was taken for all the patients. All the patients were subjected to 
a through clinical examination with regards to the presenting problem as well as 
associated co-morbid conditions. Biopsy (incision or excision) was done for all the 
patients. FNAC was done patients presented with swelling in the neck region. CT scan 
was taken for 26 patients. One patient came with MRI done outside. Plain X-Ray local 
area and CXR was taken for all the patients. 
Other routine investigations were done for all the patients for anesthetic purpose. 
Sr. Creatinine and Sr. Bilirubin was done for all the patients for assessing the fitness for 
adjuvant chemotherapy and/or radiotherapy.
Anasthetic assessment for fitness for surgery was done for 26 patients, who were 
then taken up for surgery. 14 Patients were not considered for surgery because of the 
advanced nature of their diseases and poor general condition and were offered palliative 
chemotherapy/ radiotherapy/supportive care.   
OBSERVATION
Observation
The incidence of soft tissue sarcoma in our study was as follows:
No. of Cancer Cases Soft Tissue Sarcomas Percentage
3463 40 1.15 %
The sex distribution of STS in our study was as follows:
No. of cases of STS Male Female M:F Ratio
40 31 9 3:5:1
Age specific incidence:
S.No No. of patients Male Female
0-10 yrs 1 1 Nil
11-20 yrs 1 1 Nil
21-30 yrs 4 2 2
31-40 yrs 10 7 3
41-50 yrs 10 9 1
51-60 yrs 10 7 3
61 and above 4 4 Nil
Maximum number of cases occurred between 31 and 60 years (30 cases), in our 
study  and  the  youngest  and  the  oldest  patients  were  3  years,  and  75  years  old, 
respectively.
The various clinical patients presentations of STS patients in our study were as follows:
S.No Clinical presentation No. of cases Percentage
1. Swelling 32 89 %
2. Pain 9 25 %
3. Regional L.N enlargement 3 8 %
4. Mass abdomen 2 5.5 %
5. Bony erosion 2 5.5 %
6. Wrist drop 1 3.6 %
7. Bleeding PV 1 3.6 %
6 patients presented with metastatic disease.
1 patient had a history of trauma 1 year ago.
4 patients had chronic illnesses like CAHD and diabetes mellitus.
25 patients were chronic smokers and alcohol intakers. 
8 patients were betel nut/tobacco chewers.
The site distribution of soft tissue sarcomas in our study was as follows:
Upper 
extremity
Lower
extremity
Trunk Retroperitoneal/ 
Intra abdominal
Viscera
Elbow – 6
Arm – 2
Thigh – 11
Knee – 2
Ankle– 1
Foot – 1
Shoulder – 5
Chest wall – 2
Abd. Wall – 1
Neck – 3
Back – 3
Retroperitoneal – 1
Intra abdominal – 1
Uterus – 1
The various histological types in our study were as follows:
S. No Histologic type No. of cases Percentage
1 Liposarcoma 12 30 %
2 Malignant fibrous Histio Cytoma 10 25 %
3 Fibrosarcoma 10 25 %
4 Synovial Sarcoma 3 7.5 %
5 Rhabdomyo Sarcoma 3 7.5 %
6 Haemangio Pericytoma 1 2.5 %
7 Schwannoma 1 2.5 %
Histological Grading in our study:
S.No Histological Grade No. of cases Percentage
1. High 12 30 %
2. Intermediate 10 25 %
3. Low 18 45 %
Surgical treatment given to our patients was as follows:
Surgery No of cases
Wide excision 18
Amputation 5
De – bulking 2
Partial excision 1
Treatment modalities adopted in our patients were as follows:
Treatment modality No. of cases
Surgery alone 2
Surgery + Adjuvant RT 16
Surgery + Adjuvant RT + Adjuvant CT 6
Surgery + Adjuvant CT 6
Palliative RT/CT/Supportive Care 10
Histological types to recur were as follows
S. No Histological type No. of cases
1. Malignant fibrous histiocytoma 4
2. Fibrosarcoma 3
3. Synovial sarcoma 2
4. Liposarcoma 8
5. Rhabdomyosarcoma 1
6. Schwannoma 1
Sites of recurrence were as follows:
S.No Site of recurrence No. of cases
1 Lower extremity 7
2 Upper extremity 3
3 Trunk 4
4 Others 2
Distribution by site of STS in 40 patients admitted in CMCH between May 2007 and 
October 2009
Upper extremity 20 % Trunk 35 %
Retroperitoneal / Intra – abdominal 5 % Visceral 3 %
Lower extremity 37 %
Distribution by site of STS in 3968 patients aged 16 or older admitted to Memorial 
Sloan – Kettering Cancer Center between July 1982 and July 1999
Upper extremity 14 % Trunk 11 %
Retroperitoneal / Intra – abdominal 15 % Visceral 16 %
Lower extremity 32 % Others 12 %
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DISCUSSION
DISCUSSION
Out of the 3463 cancer cases admitted in Coimbatore Medical College Hospital 
during the period of this study, only 40 cases were soft tissue sarcomas, the incidence of 
which was 1.15 %, which was similar to that found in largest centers for soft  tissue 
sarcomas like Memorial Sloan – Kettering Cancer Center.
Incidence in Male was higher than in Female. (3.5:1)
Soft tissue sarcoma was more common between the age group of 30 and 60 years, 
(75 %) in our study.
Unlike that  observed by Memorial  Sloan – Kettering Cancer  Center,  pediatric 
cases were very less in number in our study.
The most common clinical presentation in our study was swelling (89 %). Other 
symptoms  and  signs  were  pain,  lump  abdomen,  regional  lymphadenopathy,  bony 
erosion, wrist drop, bleeding PV.
The minimum duration of symptoms was 3 months; maximum was 36 months.
The minimum size of the swelling in our study was 3 cm, and the maximum was 
30 cm in greatest diameter.
The largest tumors 1) 30 cm x 25 cm 2) 25 cm x 20 cm found in our study were of 
retroperitoneal in origin. Out of these 36 cases, 20 cases were >5cm in size. This could 
be  the  evidence  that  the  patients  had  presented  themselves  very  late  for  clinical 
assessment.
6 patients presented with metastatic lung secondaries, who were eventually turned 
out to be candidates for palliative therapy/supportive care.
4 patients had other medical illnesses like CAHD, DM
1 patient had a history of trauma one year ago. Most of the patients were chronic 
smokers  and  alcoholics.  Few  were  betel  leaf/nut/tobacco  chewers.  Almost  all  the 
patients were taking mixed diet.
Site distribution
The most common site of occurrence in our study was the thigh. In general, 
maximum number of cases occurred in the lower extremity (37 %), followed by trunk 
(35 %), upper extremity (20 %), neck (8 %), retroperitoneum/intra – abdominal (5 %) 
and viscera (3 %).
Histological Types:
The most common histological type in our study was liposarcoma (30 %) as in 
Memorial Sloan – Kettering Cancer Center.
The  choice  of  appropriate  treatment  was based on tumor size,  anatomic site  and 
patient  preference.  Surgery  in  the  form of  wide  excision,  amputation  for  extremity 
lesions, debulking and partial excision was done in 26 cases.
1. Surgery alone was done, without adjuvant RT/CT, in 2 patients.
2. Surgery  +  Adjuvant  radiotherapy  (5000cGy  to  6000cGy),  was  given  in  16 
patients.
3. Surgery + Adjuvant radiotherapy + Adjuvant chemotherapy (CTX, ADR, VCR-6 
cycles) for 6 patients
4. Surgery  +  Adjuvant  chemotherapy  alone,  without  radiotherapy  for  6  patients, 
where the various treatment modalities adopted
All  the  patients  were  followed-up  at  monthly  intervals  during  the  course  of  the 
treatment with Hb %, TC, DC, Platelet count, Sr. Creatinine, Sr. Billirubin, while they 
were on adjuvant RT/CT.
After the end of treatment, patients were followed-up at 2 monthly intervals.
Mean duration of follow-up was 1 year. Maximum period of follow-up in our study 
was 21 months.
More than half of the patients did well with the above management.
Recurrence occurred in nearly 50 % of the patients in our study, whereas it is nearly 
1/3 of cases in Memorial Sloan – Kettering Cancer Center. The reason for this high 
recurrence rate in our study may be due to late presentation.
The most common histological type to recur, in our study, was Liposarcoma (42 %), 
followed by malignant fibrous histiocytoma (21 %).
Most common site of recurrence was the thigh followed by trunk.
Minimum duration for recurrence, in our study was 2 months.
Management of recurrent disease:
All the cases of recurrence, in our study were in sites amenable for wide excision/
radical surgery.
All the patients with recurrence were thoroughly investigated for metastatic disease.
1. 6  patients  with  recurrence  in  the  extremities,  were  treated  with  amputation 
followed by radiotherapy
2. 8 patients were treated with wide excision, followed by radiotherapy
3. 2 patients were treated with palliative chemotherapy.
Regular follow-up was done for these patients as done earlier. Minimum duration of 
follow-up for recurrent cases in our study was 6 months,  and the maximum was 18 
months.
One  case  recurred  in  4  months  and  another  in  10  months.  A  patient  with 
retroperitoneal liposarcoma recurred in 6 months, with metastatic lung secondaries, for 
whom, only palliative chemotherapy and supportive care could be offered.
CONCLUSION
CONCLUSION
1. The incidence of soft tissue sarcoma in Coimbatore Medical College Hospital was 
1.15%
2. There was no specific etiological factor in the patients studied.
3. Soft tissue sarcoma was common  between  31- 60 years
4. The average age incidence of each lesions corresponds to that found in the literature.
5. Most of the cases were found in the extremities, especially lower extremity.
6. Most common histopathology was liposarcoma (12 cases) in our study.
7. Pediatric cases were rare, unlike that given in the Literature.
8. Uncommon lesions like Haemangiopericytoma (1 case) and Malignant 
Schwannoma (1case) were noted
9. Biopsy, either incision or excision is mandatory for diagnosing as well as grading 
Soft Tissue Sarcomas.
10. FNAC may be helpful in cases of recurrence.
11.  Wide  excision  with  clear  margins  followed  by  adjuvant  radiotherapy  is  the 
preferred treatment of choice
12. Causes for recurrence could be higher grade of the tumors, late presentation (with 
metastasis) and inadequate surgical clearance.
13.  Monthly follow up for atleast 3 years after the end of therapy is essential for the 
early identification of recurrence and/or dissemination.
14. Recurrent  lesions  were  managed in  the same manner  as  primary  lesions.  Results 
were as good nearly as non-recurrent lesions
SUMMARY
To  summarize,  in  any  patient  presenting  with  a  soft  tissue  mass  which  is 
symptomatic or asymptomatic, is enlarging, or persisting beyond 4 to 6 weeks an early 
histological diagnosis, either by incision/excision biopsy should be made.
In  case  of  Soft  Tissue  Sarcoma,  an  early  surgical  intervention  with  adequate 
clearance, followed by adjuvant radiotherapy should be the practice, to be adopted to 
achieve better results in our setup and periodical follow-up for the early detection of 
recurrence.
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